Is there a Bearish outlook for Sage Therapeutics, Inc. (NASDAQ:SAGE) this week?

April 16, 2018 - By Adrian Erickson

Sage Therapeutics, Inc. (NASDAQ:SAGE) LogoInvestors sentiment increased to 1.49 in Q4 2017. Its up 0.28, from 1.21 in 2017Q3. It increased, as 27 investors sold Sage Therapeutics, Inc. shares while 56 reduced holdings. 63 funds opened positions while 61 raised stakes. 41.45 million shares or 7.53% more from 38.55 million shares in 2017Q3 were reported.
State Street Corporation invested in 0.01% or 1.12M shares. Proshare Advsr Ltd Liability Com holds 0.03% or 28,036 shares. Rhenman And Prtn Asset invested in 2.34% or 104,930 shares. Putnam Invests Limited Liability Com reported 5,983 shares stake. Bb Biotech Ag holds 1.04M shares or 4.84% of its portfolio. Picton Mahoney Asset has invested 0.07% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Suffolk Lc, New York-based fund reported 63,176 shares. Moreover, Dafna Cap Mgmt Lc has 2.55% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 28,800 shares. Comerica Comml Bank holds 1,343 shares. Lazard Asset Mngmt Limited has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Texas-based Smith Asset Mgmt Gru Lp has invested 0.04% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Pnc Svcs Gp has 0% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 10 shares. Cornerstone Cap Mngmt Lc reported 15,038 shares stake. Da Davidson & reported 0.01% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Citigroup reported 55,317 shares.

Since December 14, 2017, it had 0 buys, and 3 sales for $27.36 million activity. Robichaud Albert sold $9.57 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) on Thursday, December 14. Kanes Stephen also sold $7.80 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) on Wednesday, January 10.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Among 11 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SAGE Therapeutics had 23 analyst reports since October 19, 2017 according to SRatingsIntel. The firm has “Buy” rating by RBC Capital Markets given on Thursday, November 9. The company was upgraded on Thursday, December 7 by Chardan Capital Markets. BMO Capital Markets maintained it with “Buy” rating and $203.0 target in Wednesday, January 31 report. The firm earned “Buy” rating on Thursday, November 9 by BMO Capital Markets. SunTrust maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Tuesday, February 27. SunTrust has “Buy” rating and $203.0 target. The firm has “Buy” rating given on Thursday, November 9 by Cowen & Co. The company was maintained on Thursday, November 2 by RBC Capital Markets. The company was maintained on Thursday, October 19 by SunTrust. Cowen & Co maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Thursday, December 7. Cowen & Co has “Buy” rating and $202.0 target. The firm has “Buy” rating by Bank of America given on Thursday, November 16. Below is a list of Sage Therapeutics, Inc. (NASDAQ:SAGE) latest ratings and price target changes.

26/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $210.0000 Maintain
27/02/2018 Broker: SunTrust Rating: Buy New Target: $203.0 Maintain
26/02/2018 Broker: Morgan Stanley Rating: Overweight New Target: $225 Initiates Coverage On
22/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $277.0 Maintain
31/01/2018 Broker: BMO Capital Markets Rating: Buy New Target: $203.0 Maintain
07/12/2017 Broker: Cowen & Co Rating: Buy New Target: $202.0 Maintain
07/12/2017 Broker: SunTrust Rating: Buy New Target: $178.0 Maintain
07/12/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $198.0 Maintain
07/12/2017 Broker: BMO Capital Markets Rating: Buy New Target: $203.0 Maintain
07/12/2017 Broker: Chardan Capital Markets Rating: Buy Upgrade

The stock decreased 3.24% or $5.53 during the last trading session, reaching $165.05. About 178,699 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 135.95% since April 16, 2017 and is uptrending. It has outperformed by 124.40% the S&P500.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $7.56 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.